Arena Pharmaceuticals

Aristea Halts Clinical Trial, Dissolves Company

Safety findings in Phase 2 clinical trials have forced Aristea Therapeutics to stop developing its lead candidate RIST4721 for treating serious immune-mediated inflammatory diseases. As a consequence, Aristea’s management has decided to dissolve the company.

Vivus Obesity Pill Prescriptions Jump 68%

FDA OKs First Obesity Drug in 13 years